Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC

NIK-333(Peretinoin) PhaseⅢ Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus(HCV)-Positive Hepatocellular Carcinoma(HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study

The purpose of this study is to verify the superiority of NIK-333 (Peretinoin) to placebo in inhibiting the recurrence of HCV-positive HCC in patients showing complete cure of the disease, with the recurrence-free survival as the primary endpoint, in a multi-center, randomized, double-blind, placebo-controlled, parallel-group comparison study.

Study Overview

• Status: Completed
• Conditions: Hepatic Neoplasm Malignant Recurrent
• Intervention / Treatment: Drug: NIK-333(peretinoin); Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 616
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Chiba, Japan, 260-0856
  • Fukuoka, Japan, 810-8563
  • Fukuoka, Japan, 814-0180
  • Gifu, Japan, 500-8513
  • Gifu, Japan, 501-1194
  • Hiroshima, Japan, 734-8530
  • Hiroshima, Japan, 734-8551
  • Kagoshima, Japan, 890-8520
  • Kumamoto, Japan, 860-0811
  • Nagasaki, Japan, 852-8501
  • Niigata, Japan, 950-1104
  • Oita, Japan, 879-5593
  • Okayama, Japan, 700-8558
  • Osaka, Japan, 540-0006
  • Osaka, Japan, 534-0021
  • Osaka, Japan, 537-8511
  • Osaka, Japan, 543-8555
  • Osaka, Japan, 545-8586
  • Saga, Japan, 840-8571
  • Saga, Japan, 849-8501
  • Tokushima, Japan, 770-8503
  • Tokushima, Japan, 770-8539
  • Wakayama, Japan, 641-8510
  • Aichi
    • Nagoya, Aichi, Japan, 466-0065
    • Nagoya, Aichi, Japan, 467-0001
  • Chiba
    • Kashiwa, Chiba, Japan, 277-8577
  • Ehime
    • Matsuyama, Ehime, Japan, 790-0826
  • Fukuoka
    • Iizuka, Fukuoka, Japan, 820-0018
    • Kurume, Fukuoka, Japan, 830-0011
  • Gifu
    • Ogaki, Gifu, Japan, 503-0864
  • Hokkaido
    • Sapporo, Hokkaido, Japan, 060-0033
    • Sapporo, Hokkaido, Japan, 006-8555
    • Sapporo, Hokkaido, Japan, 060-8648
  • Hyogo
    • Himeji, Hyogo, Japan, 670-0063
    • Kobe, Hyogo, Japan, 650-0047
    • Nishinomiya, Hyogo, Japan, 663-8501
  • Ishikawa
    • Kanazawa, Ishikawa, Japan, 920-8641
  • Kanagawa
    • Kawasaki, Kanagawa, Japan, 213-8587
    • Sagamihara, Kanagawa, Japan, 228-8520
    • Sagamihara, Kanagawa, Japan, 252-0375
    • Yokohama, Kanagawa, Japan, 232-0024
    • Yokohama, Kanagawa, Japan, 241-0815
  • Kochi
    • Nankoku, Kochi, Japan, 783-8505
  • Okayama
    • Kurashiki, Okayama, Japan, 701-0192
  • Osaka
    • Ikeda, Osaka, Japan, 563-8510
    • Moriguchi, Osaka, Japan, 570-8507
    • Osakasayama, Osaka, Japan, 589-8511
    • Sakai, Osaka, Japan, 591-8025
    • Suita, Osaka, Japan, 565-0871
  • Saitama
    • Iruma, Saitama, Japan, 350-0495
  • Shizuoka
    • Sunto-gun, Shizuoka, Japan, 411-8777
  • Tochigi
    • Shimotsuke, Tochigi, Japan, 329-0498
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-0021
    • Bunkyo-ku, Tokyo, Japan, 113-8655
    • Bunkyo-ku,, Tokyo, Japan, 113-8519
    • Chiyoda-ku, Tokyo, Japan, 101-8643
    • Chuo-ku, Tokyo, Japan, 104-0045
    • Minato-ku, Tokyo, Japan, 105-8470
    • Ota-ku, Tokyo, Japan, 143-8541
    • Setagaya-ku, Tokyo, Japan, 158-8531
    • Shibuya-ku, Tokyo, Japan, 150-8935
    • Shinjuku-ku, Tokyo, Japan, 160-0023
  • Tokyo,
    • Musashino, Tokyo,, Japan, 180-8610
  • Yamaguchi
    • Shimonoseki, Yamaguchi, Japan, 750-0061
    • Ube, Yamaguchi, Japan, 755-8505
  • Yamanashi
    • Kofu, Yamanashi, Japan, 400-8506

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients with HCV-positive HCC who meet the following conditions before radical treatment

   • Patients diagnosed as having typical HCC on dynamic CT,CTA/CTAP, or dynamic MRI (nodule visualized as a high signal intensity area in the arterial phase and as a relatively low signal intensity area in the portal and equilibrium phases) performed within 8 weeks (56 days) before treatment start prior to radical therapy
   • Patients with the first primary HCC or the first recurrence of primary HCC
2. Patients who received the radical therapies. The treatment duration (from the start to the end of the treatment) should be within 4 weeks (28 days) for each of the radical therapies.
3. Patients showing a complete cure, as confirmed by the dynamic CT images taken from 8 weeks (56 days) to 12 weeks (84 days) after the end of the treatment show a non-stained low-concentration area overlapping the tumor image observed before complete cure.
4. Patients who are able to begin treatment with the study drug within 8 weeks (56 days) after dynamic CT to confirm complete cure

5. Patients confirmed of satisfying the following conditions based on the screening performed at subject registration

   • Positive for serum hepatitis C virus nucleic acid (HCV-RNA)
   • Grade A on Child-Pugh classification
   • Platelet count of 50 000/µL or higher
6. Patients with ECOG Performance Status score of 0 to 1
7. Patients of the age of 20 years or older at the time of informed consent

Exclusion Criteria:

1. Patients positive for HBs antigen
2. Patients showing vascular invasion of HCC on imaging diagnosis
3. Patients who have also undergone transcatheter arterial embolization therapy (TAE/TACE), transarterial infusion therapy (TAI), and chemolipiodolization in combination with the radical therapy
4. 4 Patients who want to receive antiviral therapy such as concomitant therapy with intaferon during the study period
5. Patients who have received other study drugs, anticancer drugs, or interferons after radical therapy
6. Patients who have hypertension as a complication, and whose blood pressure cannot be controlled by drug therapy (systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 100 mmHg or higher, as determined at subject registration)
7. Patients who have a history of allergy to CT contrast media, and whose participation in this study is judged to be inappropriate by the investigator or the subinvestigator
8. Patients with a history of total gastrectomy
9. Patients with a history of cardiac arrest

10. Patients with any of the following laboratory values or complications

    • Creatinine>= 1.5mg/dL
    • Albumin urine >= 1000mg/g Creatinine
    • Cardiac disorder corresponding to CTC-AE grade 3 in severity
    • HbA1c >= 7.4 under treatment with insulin
    • Autoimmune disease or asthma being treated with oral steroid
11. Patients confirmed of having another malignant neoplasm or who had undergone a radical therapy of HCC within the past 5 years to treat another malignant neoplasm (however, this does not apply to endoscopic resection and resection of intraepithelial carcinoma)
12. Patients who are pregnant, who have a possibility of being pregnant or who have a desire to become pregnant during the study period
13. Lactating women
14. Patients who have a history of allergy to retinoid-related substances (vitamin A, etc.) in the past
15. Patients who participated in another clinical study within past 6 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo (8 x Placebo capsules) orally, twice a day
Experimental: NIK-333(peretinoin)	Drug: NIK-333(peretinoin); 600mg (8 x 75mg capsules) orally, twice a day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recurrence-free Survival	HCC recurrence was defined as the appearance of new intrahepatic lesions which was confirmed based on findings of hypervascularity (nodules enhanced in the arterial phase and washout in the late phase) by dynamic CT images, or a new extrahepatic metastasis. Recurrence of intrahepatic HCC was evaluated by an independent image reading committee. RFS was defined as the time from randomization to HCC recurrence or death from any cause, whichever occurred first. For subjects who terminated the study without HCC recurrence or death, RFS was censored at the day of the latest dynamic CT examination.	Date of randomization to the date of recurrence of HCC (followed every 12 weeks) or death (whichever occurs first)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease-free Survival	DFS was defined as the time from randomization to HCC recurrence, death from any cause or occurrence of secondary cancer (malignant tumors other than HCC), whichever occurred first. For subjects who terminated the study without HCC recurrence, death, or occurrence of secondary cancer, DFS was censored at the day of the latest dynamic CT examination.	Date of randomization to the date of recurrence of HCC (followed every 12 weeks), death, or secondary cancer (malignant tumors other than HCC)(whichever occurs first)
Time to Recurrence	TTR was defined as the time from randomization to HCC recurrence. For subjects who terminated the study without HCC recurrence, TTR was censored at the day of the latest dynamic CT examination.	Date of randomization to the date of recurrence of HCC(followed every 12 weeks)

Collaborators and Investigators

• Sponsor: Kowa Company, Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2012
• Primary Completion (Actual): October 1, 2016
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: July 10, 2012
• First Submitted That Met QC Criteria: July 13, 2012
• First Posted (Estimate): July 16, 2012

Study Record Updates

• Last Update Posted (Actual): December 2, 2020
• Last Update Submitted That Met QC Criteria: November 29, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Neoplasms by Site; Disease Attributes; Digestive System Neoplasms; Liver Diseases; Neoplasms; Recurrence; Liver Neoplasms
• Other Study ID Numbers: NIK-333-05